Valneva SE — Q1 2023 Form 6-K Summary
Business context and reporting period
Valneva SE filed a Form 6-K on May 4, 2023, reporting unaudited interim consolidated results for the three months ended March 31, 2023. The filing includes a press release and unaudited condensed consolidated financial statements. Valneva is a vaccine company; the filing text provided does not include the full business or product commentary from the press release.
Key financial metrics
| Metric | Q1 2023 | Q1 2022 | Change |
|---|---|---|---|
| Product sales | €32.1 million | €16.2 million | Up 98.6% |
| Other revenues | €1.4 million | €5.7 million | Down 75.2% |
| Total revenues | €33.5 million | €21.8 million | Up 53.4% |
| Operating loss | €16.6 million | €18.4 million | Improved by €1.8 million |
| Loss before tax | €18.2 million | €25.5 million | Improved by €7.3 million |
| Net loss | €18.1 million | €26.0 million | Improved by €7.9 million |
| Basic loss per share | €0.13 | €0.24 | Improved |
| Net cash used in operating activities | €24.3 million | €26.9 million | Improved by €2.5 million |
Revenue increased primarily because of higher product sales, while other revenues declined. The operating margin was approximately negative 49.5% versus negative 84.3% in the prior-year quarter; the net margin was approximately negative 54.1% versus negative 119.2%.
Balance sheet, debt, and liquidity
- Cash and cash equivalents were €254.5 million at March 31, 2023, compared with €289.4 million at December 31, 2022 and €311.3 million at March 31, 2022.
- Total assets were €590.0 million, down from €621.3 million at December 31, 2022.
- Equity was €204.8 million, compared with €219.8 million at December 31, 2022.
- Borrowings totaled €97.4 million, comprising €83.2 million of non-current borrowings and €14.2 million of current borrowings. Lease liabilities totaled €55.3 million.
- Current liabilities were €263.3 million, including €135.3 million of current refund liabilities. The filing does not provide a stated undrawn credit-facility amount or other specific liquidity headroom.
Cash flow and material changes
- Net cash decreased by €31.7 million during the quarter, ending at €254.5 million. The decrease compares with a €35.3 million decrease in Q1 2022.
- Operating cash use improved to €24.3 million from €26.9 million, but working capital consumed €13.9 million compared with a €11.2 million benefit in Q1 2022.
- Investing cash use declined to €3.6 million from €9.4 million, reflecting lower property, plant, and equipment purchases.
- Financing cash use was €3.8 million versus €1.0 million of financing cash generation in Q1 2022. Q1 2023 included €2.7 million of interest paid and €0.9 million of lease payments.
- Research and development expenses decreased to €14.1 million from €20.7 million, while marketing and distribution expenses increased to €9.0 million from €2.0 million and general and administrative expenses increased to €10.0 million from €5.8 million.
Outlook, risks, and unusual items
The supplied filing text does not provide clear numerical guidance, updated full-year outlook, or detailed management commentary. Investors should review Exhibit 99.1 for any guidance or operational updates not included in the supplied text.
Other income and expenses, net, were €3.5 million in Q1 2023 versus €2.1 million in Q1 2022. A €3.2 million net foreign-exchange gain in Q1 2023 compared with a €2.4 million loss in Q1 2022 materially benefited the period’s pretax result. Finance expenses were €5.1 million, compared with €4.7 million in the prior-year quarter.
The financial statements are unaudited. The filing text does not identify specific legal contingencies, supply risks, product-development risks, or regulatory matters beyond the financial statement data provided.
Important facts to verify
- Review the full Exhibit 99.1 press release for product-level sales drivers, vaccine launch status, and management’s full-year guidance.
- Verify the composition, timing, and potential cash impact of the €135.3 million current refund liabilities.
- Assess the sustainability of the €254.5 million cash balance against continuing operating cash use, debt maturities, lease obligations, and planned investments.
- Confirm the causes of higher marketing, distribution, and general and administrative expenses.
- Review currency exposure and the extent to which the Q1 foreign-exchange gain may not recur.